Abstract
We previously identified an HLA-A2. I-restricted epitope within the RCC-associated antigen G250 that is recognized by CTLs. Using DCs of healthy individuals, which were loaded with overlapping 20 mer G250-derived peptides, we here report the induction of CD4+ T cells that recognize the G250 peptide of amino acids 249-268. Moreover, naturally processed G250 protein is readily recognized by these G250-specific CD4+ T cells in the context of HLA-DR molecules. Interestingly, peptide G250:249-268 overlaps the previously identified HLA-A2. I-restricted G250 epitope recognized by CTLs. These data and the high prevalence of G250 in RCC patients make peptide G250:249-268 a potential target in peptide-based vaccines to induce both CD4+ and CD8+ T-cell responses in patients.
Original language | English |
---|---|
Pages (from-to) | 441-444 |
Number of pages | 4 |
Journal | International Journal of Cancer |
Volume | 100 |
Issue number | 4 |
DOIs | |
State | Published - 1 Aug 2002 |
Externally published | Yes |
Keywords
- G250
- Human leukocyte antigen class II
- MN/CA IX
- Renal cell carcinoma
- T-helper cell